Procter & Gamble Hygiene and Health Care Ltd
- P/E
- 28.3x
- 52-week range
- 6,579 – 13,497
- ROE
- 115%
- ROCE
- 157%
- Sector
- Personal Products
- Industry
- Personal Care
- Listed on
- NSE, BSE
About
Procter & Gamble Hygiene and Health Care Limited is an India-based fast-moving consumer goods (FMCG) company. The Company is engaged in manufacturing and selling branded packaged FMCG in the feminine care and healthcare businesses. The Company has two segments: Health care products and Hygiene products. The health care products segment comprises ointment and creams, cough drops and tablets. The Hygiene products segment comprises feminine hygiene products and other skin care hygiene products. Its brands include Pampers, Ariel, Tide, Whisper, Gillette, Head & Shoulders, Herbal Essences, Pantene, Ambi Pur, Oral-B, Vicks, Olay, and Old Spice. Its healthcare portfolio includes Vicks VapoRub, Vicks Cough Drops, Vicks Action 500 Advanced, Zzzquil, Vicks Inhaler, Vicks Xtra Strong Rub, Vicks Baby Rub, Vicks VapoRub Steam Pods, Vicks Headache Roll-on and Vicks Cough Syrup. Its Feminine hygiene portfolio includes Whisper Ultra, Whisper Choice, Whisper Ultra Skin Love, among others.
Quick check
The five things to look at first. Open one for more.
Compared with its industry
Personal Care: 22 companies →Procter & Gamble Hygiene and Health Care Ltd against the typical company in its industry. The rank is out of the companies that report each figure; green means the better quarter of the pack, red the worse quarter.
- Valuation (P/E)28.3 against a typical 33.9: cheaper than most peers (1st = cheapest).8th of 22
- Sales growth−4.9% against a typical +14.9% from a year earlier.12th of 15
- Profit growth−34.4% against a typical +8.9% from a year earlier.11th of 13
- Share price, 3 months−19.6% against a typical −7.5%.15th of 19
Board meetings
Results dates and other board meetings. Full calendar
| Details | ||
|---|---|---|
| 12 Nov 2026Upcoming | Financial Results | To consider and approve the financial results for the period ended September 30, 2026 |
| 29 Jul 2026 | Financial Results | To consider and approve the financial results for the quarter ended Jun 30, 2026 |
| 28 May 2026 | Financial Results/Dividend | To consider and approve Audited Financial Statements for the Financial Year ending on March 31, 2026 and recommendation of final dividend, if any |
| 30 Jan 2026 | Financial Results/Dividend | To consider and approve the financial results for the period ended December 31, 2025 and dividend, if any |
| 6 Nov 2025 | Financial Results/Dividend | To consider and approve the financial results for the period ended September 30, 2025 and dividend |
| 30 Jul 2025 | Financial Results | To consider and approve the unaudited financial results for the period ended Jun 30, 2025 |
| 27 May 2025 | Financial Results/Dividend | We would like to inform you that a meeting of the Board of Directors of the Company is scheduled to be held on Tuesday, May 27, 2025, inter alia, to consider and approve Audited Financial Results and Statements for the Financial Year ended March 31,2025 and to consider recommendation of dividend, if any. |
Financials
Standalone figures in ₹ crore.
| ₹ Cr. | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 1,138 | 1,133 | 1,002 | 932 | 1,135 | 1,248 | 992 | 937 | 1,150 | 1,262 | 941 | 891 |
| Expenses | 853 | 824 | 745 | 813 | 845 | 877 | 782 | 671 | 865 | 860 | 723 | 721 |
| Operating Profit | 285 | 310 | 257 | 118 | 290 | 371 | 210 | 266 | 285 | 402 | 218 | 170 |
| OPM % | 25% | 27% | 26% | 13% | 26% | 30% | 21% | 28% | 25% | 32% | 23% | 19% |
| Other Income | 16 | 16 | 14 | 7 | 8 | 10 | 19 | 8 | 10 | 12 | 12 | 9 |
| Interest | 2 | 3 | 22 | 0 | 2 | 7 | 6 | 0 | 4 | 3 | 3 | 0 |
| Depreciation | 14 | 14 | 15 | 13 | 12 | 10 | 10 | 9 | 9 | 10 | 10 | 10 |
| Profit before tax | 284 | 309 | 234 | 112 | 285 | 364 | 213 | 265 | 282 | 402 | 218 | 170 |
| Tax % | 26% | 26% | 34% | 28% | 26% | 26% | 27% | 27% | 26% | 25% | 30% | 26% |
| Net Profit | 211 | 229 | 154 | 81 | 212 | 269 | 156 | 192 | 210 | 301 | 153 | 126 |
| EPS in Rs | 64.91 | 70.52 | 47.56 | 24.97 | 65.28 | 82.74 | 48.09 | 59.17 | 64.65 | 92.87 | 47.17 | 38.9 |
Growth and returns
Compounded yearly rates over each period.
- 10 Years
- 6%
- 5 Years
- 7%
- 3 Years
- 3%
- TTM
- −2%
- 10 Years
- 9%
- 5 Years
- 15%
- 3 Years
- 14%
- TTM
- −5%
- 10 Years
- 2%
- 5 Years
- −9%
- 3 Years
- −19%
- TTM
- —
- 10 Years
- 60%
- 5 Years
- 83%
- 3 Years
- 89%
- TTM
- —
P/E and EPS over time
Daily P/E and trailing 12-month EPS. EPS updates with each result.
Peers
Listed companies in the same business.
| Procter & Gamble Hygiene and Health Care Ltd | ₹ 6,910.00 | — | 28.3x | — | 115% | — |
| Hindustan Unilever | ₹ 1,820.00 | ₹ 4,27,626 Cr. | 43.4x | 9.3x | 0% | 0% |
| Marico | ₹ 764.10 | ₹ 99,347 Cr. | 59.1x | 24.7x | 0% | 0% |
| Godrej Consumer Products | ₹ 851.50 | ₹ 87,134 Cr. | 43.7x | 7x | 0% | 0% |
| Dabur India | ₹ 366.00 | ₹ 64,927 Cr. | 35.2x | 5.8x | 0% | 0% |
| Cupid | ₹ 306.50 | ₹ 41,214 Cr. | 347.9x | 83.5x | 0% | 0% |
Management
- Srividya Srinivasan
- Chief Financial Officer, Executive Director
- Mukta Maheshwari
- Chief Marketing Officer
- Kumar Venkatasubramanian
- Managing Director, Executive Director
Prices are delayed and for information only. Nothing on this page is investment advice.